Roche is 'well placed' for U.S. pricing tussle, CEO says

Worried about how mounting pricing pushback will affect Roche ($RHHBY)? Don't be, CEO Severin Schwan told Swiss newspaper Finanz und Wirtschaft. "Pressure will rise on drugs that are less sophisticated. But the United States will still offer an environment that supports and rewards real innovation," he pointed out. "Roche is well placed." And in the meantime, don't fret too much about the company's pipeline prospects, either, he said. With up to 6 new active pharmaceutical ingredients that could be approved within two years, "it is not at all the case anymore that everything has to succeed in terms of what lies ahead with the pipeline in the near term. If even a part succeeds, we are on course for further sustainable sales growth," he told the paper. More

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.